US 4282287

I'll run targeted searches for this specific patent number, including any CAFC 2026 activity.

Let me check for any litigation, PTAB, or CAFC activity and confirm the reissue lineage.

US 4,282,287 A — Summary

Searches run: USPTO/Google Patents full text, uspto.report, FreePatentsOnline classification listings, EPO Global Patent Index, and open-web queries for "4282287" + CAFC/2026. I found no CAFC 2026 docket entry, PTAB proceeding, or any litigation involving this patent. I want to be explicit about that rather than infer one: US 4,282,287 is long expired, which makes a 2026 Federal Circuit appeal essentially impossible. Details below.

Bibliographic data

Assignee caveat: Google Patents/report and uspto.report both list the assignee simply as "Individual." I did not find an assignment record to Northeastern University or any other institution, even though the inventor's research group is identified with that institution in the cited literature. Treat "Individual" as the record value and do not assume an institutional owner.

Abstract (verbatim)

"A multiple-layer process for applying, in alternate, successive layers, the protein, avidin, and a biotin-containing extender material to a solid surface to modify the properties of the surface and to the multiple-layer product so prepared."

Independent claims in plain language

Claim 1 — the core process claim. A process of modifying a surface's properties by applying alternating, monomolecular, successive layers of two materials: (1) avidin and (2) a noncovalent, biotin-modified "extender." One of the two materials is reacted/attached to the surface to start, and then at least one additional layer of each material is applied in alternation, each secured and reacted to the layer beneath, finishing with either avidin or the extender as the top layer.

Key elements a reader should note: "alternate," "monomolecular," "successive," "noncovalent" extender, and "at least one additional layer of each" (i.e., a minimum of roughly two cycles — see claims 15 and 16, which set out three-or-more and two-layer embodiments).

Claim 21 — the narrower polymer-specific process claim. A "monomolecular-layering process" on a polymer substrate, recited step-by-step with washes:

• (a) apply biotin-N-hydroxysuccinimide (biotin-NHS) ester as the biotin-extender to the polymer surface so it reacts with the polymer;
• (b) wash off unreacted biotin-NHS;
• (c) apply avidin so it reacts with the bound biotin-NHS;
• (d) wash off unreacted avidin;
• (e) apply caproylamidobiotin NHS or RNase as biotin-extender;
• (f) wash off unreacted extender;
• (g) recover the polymer with multiple layers, top layer being biotin-extender.

This claim is where the specification's worked example (Affigel-701 aminoethyl polyacrylamide beads, §"EXAMPLE," and FIG. 2) is captured.

Everything else is dependent. Claims 2–18 depend from claim 1 (top layer = extender; modified avidin; biotin pretreatment; concentration increasing/decreasing/constant; polymeric or erythrocyte surfaces; amino polyacrylamide particles; two vs. three-or-more layers; signal extenders such as biotin-horseradish peroxidase or biotin-ribonuclease). Claims 19, 20, 26, 27 and 28 are product-by-process claims ("layering system produced by the process of claim …"), and claims 22–25 depend from claim 21.

Literal-text notes (no auto-correction): Claim 1 as printed reads "first and and second materials"; claim 23 reads "biotinextender" as one word; claim 25 is spelled "proces." These are transcription artifacts in the printed/served copy, not different claim scopes, but I am flagging them because you asked for literal interpretation.

Legal-procedural context

• Reissue: A reissue application was filed December 6, 1983 (effective September 14, 1983), resulting in US RE31,712 E, "Biochemical avidin-biotin multiple-layer system," which reissued October 23, 1984. Any post-1984 enforcement of this disclosure would run through the reissue, not through the original 4,282,287.
• Family (all sharing the Jan. 24, 1980 priority): US 4,478,914 ("Process for applying multiple layers of a protein and a ligand extender to a surface…", filed from Ser. No. 532,036); US 4,656,252 ("Amidobiotin compounds useful in an avidin-biotin multiple layering process," filed from Ser. No. 616,851); and an abandoned continuation-in-part, US Ser. No. 272,297 (filed June 10, 1981).
• Prior art cited on the face: US 4,132,528 (Eastman Kodak), US 4,134,792 (Miles Labs), US 4,168,300 (AB Kabi); non-patent literature: Bayer et al., Trends in Biochemical Science 3, N257 (Nov. 1978); Costello et al., Clin. Chem. 25(9), 1572 (1979); Jasiewicz et al., Exp. Cell Res. 100, 213 (1976).
• Forward citation weight: 113 third-party forward citations (75 in the examiner-cited listing), including Affymetrix's "Combinatorial strategies for polymer synthesis" family and Accelerate Diagnostics' later purification patents — indicating this patent is treated as foundational art for layered/avidin-biotin surface chemistry.

Explicit uncertainty

• CAFC 2026 docket: No results. I cannot confirm the existence of any 2026 appellate activity because none surfaced, and the patent's docketed status is expired/ceased as of January 24, 2000. If you have a specific docket number or case caption, give it to me and I'll run it directly rather than searching by patent number.
• Assignee: The record says "Individual." I have not verified whether any assignment (to Northeastern University or a licensee) was ever recorded with the USPTO Assignment Branch; that would need a separate Assignment database pull.
• I have not verified the current claim text against the USPTO Patent Center certified copy; the text above is taken from the Google Patents full-text render of US 4,282,287 A, which matches the uspto.report rendering word-for-word including the typographical artifacts.

Sources: https://patents.google.com/patent/[US4282287A](/patent/US4282287A)/en · https://uspto.report/patent/grant/4282287 · https://patents.google.com/patent/USRE31712E/en · https://uspto.report/patent/grant/[4,656,252](/patent/4656252)

I'll research litigation involving US patent 4282287 using litigation-focused sources.

Let me check litigation-specific databases directly.

Found a promising lead — a case captioned Giese v. Pierce Chemical Co. Let me dig into it.

I'll verify the structured data against web sources and check for any PTAB activity that may not be in the ODP ingest, plus chase the litigation lead already surfaced.

Let me confirm there's no AIA trial against the '287 or its reissue/continuation family, and check whether the reexamination history is being conflated with PTAB activity.

PTAB / AIA Trial Proceedings — US 4,282,287

Proceedings overview

Total AIA trial proceedings on file: zero. The USPTO Open Data Portal structured block returned no IPR, PGR, or CBM proceeding naming US 4,282,287 (or its reissue, US RE31,712 E), and targeted web searches of PTAB E2E-adjacent sources and the general web surfaced none. There is no proceeding to characterize as active, invalidated, sustained, settled, or denied institution.

Bottom line for a defendant: you cannot build a PTAB-based defense to this patent because no AIA trial was ever filed against it — but that is not the reassuring signal it would normally be for a patent owner. It reflects the patent's expiry on 2000-01-24, roughly twelve years before the first IPR was even available (AIA trials became available 2012-09-16). The absence of PTAB activity here means "no one needed to file," not "the patent is hardened." More importantly for anyone receiving a demand letter citing this family, the real claim-killing happened elsewhere: a 1997 ex parte reexamination certificate and a 1999 district court summary judgment in Giese v. Pierce Chemical Co. those are not PTAB proceedings, but they are the reason claims in the sibling patent are dead — see the "No PTAB proceedings" entry below.

No PTAB proceedings — the canonical list is empty

{none} — no petitioner v. Roger W. Giese

• Type: N/A — no Inter Partes Review, Post-Grant Review, or Covered Business Method review was ever instituted or even petitioned against US 4,282,287.
• Filed: N/A
• Status: N/A (canonical structured source: "The USPTO ODP API returns no AIA trial proceedings for this patent as of the most recent ingest.")
• Judge panel: N/A
• Petition grounds: N/A
• Institution decision: N/A
• Final Written Decision: N/A — not issued; there is no claim-level disposition to report, and I will not manufacture one.
• Settlement / termination: N/A
• Appeal: I found no Federal Circuit appeal arising from a PTAB proceeding. (The Federal Circuit activity in this patent family, if any, would have run through the 1999 district court judgment discussed below — I did not find a reported CAFC opinion on the '287 itself.)
• Defensive value: None directly. An IPR-style argument is off the table as a strategic matter because the patent is expired; the useful defensive posture is the prior reexam/court record against the sibling claims, not anything from the Board.

Why there is no PTAB history (structural, not strategic)

Three independent reasons, each of which a defendant should understand before treating "no IPRs" as favorable:

1. Timing. US 4,282,287 issued 1981-08-04 and expired 2000-01-24 (status "Ceased"). IPR/PGR/CBM did not exist until the AIA's trial provisions took effect 2012-09-16. The patent was already dead when the forum opened.
2. Post-grant review is statutorily unavailable. PGR reaches only patents with an effective filing date on or after 2012-03-16. The '287 priority date is 1980-01-24. CBM review was likewise inapplicable (no financial-services business-method subject matter, and the CBM program has since sunset).
3. The family was litigated the old-fashioned way. Disputes over this disclosure were resolved in ex parte reexamination and in district court, not at the Board.

The closest analogues to a PTAB outcome — and why they matter more here

I am flagging these explicitly as NOT PTAB proceedings, because a defendant who conflates them will mis-assess the estate. But they are the only claim-level dispositions of consequence in this family.

Ex parte reexamination of US 4,478,914 (Reexam Certificate B1) — not an AIA trial

• Proceeding type: Ex parte reexamination under 35 U.S.C. §§ 301–307 — examiner-driven, no PTAB involvement, no petitioner participation.
• Requester: The patent owner himself, Roger W. Giese, filed 1995-05-11 "in light of additional 'prior art' that had recently been brought to his attention." (Per Giese v. Pierce Chemical Co., 43 F. Supp. 2d 98 (D. Mass. 1999-03-05).)
• Certificate: Reexamination Certificate B1, 4,478,914 issued 1997-06-17.
• Claim-level outcome (from the district court's construction, not from a PTAB FWD):
  • Reexamined claim 25 omitted the original claim's "washing the surface between each applying step to remove unreacted first or second material" step.
  • The court held this an impermissible enlargement under § 305, citing Quantum Corp. v. Rodime, 65 F.3d 1577, 1580 (Fed. Cir. 1995), and invalidated claim 25 — both the reexamined version and the original.
  • Claim 27 (product-by-process, "produced by the process of claim 25") was invalidated on the ground that a product claim defined only by reference to an invalid process claim is not "sufficiently described" (Holland Furniture Co. v. Perkins Glue Co., 277 U.S. 245, 254 (1928)).
  • Claims 43–73 (added during reexamination and dependent on claim 25) were invalidated.
  • Claim 54 (the "addition" reintroducing the washing step) was invalidated as an attempted § 305 safe harbor — "the dependent claim tail cannot wag the independent claim dog" (North American Vaccine v. American Cyanamid, 7 F.3d 1571, 1577 (Fed. Cir. 1993)).
  • Claim 26 survived the summary-judgment stage; the court applied the § 282 presumption of validity and denied judgment, deferring the question until after verdict.
• Defensive value: This is the usable precedent. If a demand letter asserts claim 25, 27, 43–73, or 54 of the '914 patent, those claims were held invalid by a federal court in 1999. Note the precision required: the holding is about the '914 patent, and it says nothing on its face about the '287 claims — the '287's own claim set was never adjudicated invalid in this record.

Giese v. Pierce Chemical Co. — district court, not PTAB

• Court / docket: D. Mass., Civ. A. Nos. 97-12561-WGY and 97-12562-WGY (Chief Judge Young).
• Opinions: 29 F. Supp. 2d 33 (D. Mass. 1998) and 43 F. Supp. 2d 98 (D. Mass. 1999-03-05).
• Patents asserted: Re. 31,712 (the reissue of the '287) and B1 4,478,914. Giese included no count for direct infringement — the theories were contributory infringement and inducement under § 271(b)–(c), premised on end-user direct infringement.
• Defendants: Pierce Chemical Co. and Vector Laboratories, Inc., sellers of the "Vectastain ABC Kit."
• Outcomes of note:
  • Claim construction: the Vectastain "preformed complex" is not monomolecular (undisputed after Dr. Riordan conceded it on direct examination). The court noted that non-infringement of claim 1 of the '712 would appear to follow, but made no such ruling because Vector had not requested it.
  • Experimental use: summary judgment of non-infringement denied — the court held a profit motive does not strip the defense, but defendants failed to prove end-users qualified.
  • Laches: granted on 1998-12-02, wiping out lost profits and prejudgment damages.
  • Inequitable conduct: the defense was waived (failure to plead; leave to amend denied).
• Defensive value: Laches and the district court's claim constructions are court-side tools, not Board-side ones. The laches holding is of limited modern utility after SCA Hygiene v. First Quality (2014) (no laches as a defense to damages for infringement within § 286's six-year lookback).

Strategic summary

Canceled vs. sustained vs. untested. There is no PTAB certificate in this family, so there is no AIA cancellation to cite. The claim-level scoreboard that exists comes from the '914 reexamination/§ 305 line of cases: canceled/invalidated — '914 claims 25, 27, 43–73, 54; survived summary judgment — '914 claim 26; untested — the '287 claim set (claims 1–28 as issued), which appears never to have been held invalid. The '287 is not even the operative enforcement vehicle post-1984: US RE31,712 E reissued 1984-10-23 and superseded it. Any assertion today would have to run through the reissue or the sibling '914 / '252, not through the original '287.

Estoppel landscape. Section 315(e)(2) estoppel is inapplicable — it attaches only to a petitioner, its real parties in interest, and privies, and only after institution and an FWD. With no petition ever filed, there is no statutory estoppel barring anyone. That cuts both ways: a defendant is free to raise any § 102/§ 103 ground, but also gains no benefit from an earlier petitioner's work product. The practical constraint is not estoppel but expiry and preclusion by court judgment — the 1999 invalidity determinations on the '914 claims are binding as between those parties and their privies, and issue preclusion may reach repeat litigants.

Pattern signals. No repeat petitioners (none exist). No patent-owner PTAB appeal strategy — Giese never had a PTAB case to appeal. No defensive aggregator (Unified Patents, RPX, or similar) is in the chain; those entities target asserted, in-force patents, and this family was expired before they formed. The cited Board involvement in this history is BPAI, and it was prosecution advocacy on the separate '609 patent (finding no § 102 rejection and no prima facie § 103 case over the '287) — not an AIA trial and not a validity proceeding against the '287.

One contradiction to flag. The previously generated patent summary describes the family's enforcement posture without noting the 1999 invalidity of '914 claims 25, 27, 43–73. That is not a conflict with the bibliographic data, but it is a material omission for a defendant: the '914 is a materially narrowed asset and should not be described as a live, broad claim set.

Recommended next steps

1. If you are a defendant and the demand cites the '914 patent, lead with Giese v. Pierce Chemical Co., 43 F. Supp. 2d 98 (D. Mass. 1999-03-05): claims 25, 27, 43–73 and 54 were held invalid for impermissible enlargement under 35 U.S.C. § 305, and claim 25's invalidity reaches the original claim as well. Link the opinion: CourtListener 2472263 and the 1998 companion opinion at CourtListener 2423014.
2. If the demand cites US 4,282,287 or RE31,712, check the dates first. Both expired 2000-01-24 and 2001-10-23 respectively — and note the 1999 expert calculation of a "patent period in October 23, 2001" consistent with the reissue term. Any assertion of a live patent on this disclosure is facially defective; the only defensible theory is a continuation or a different patent claiming priority to it.
3. If you want to invalidate a still-live relative of this family, the PTAB is now a hostile venue for institutional reasons that have nothing to do with this patent: as of the 2025–2026 rulemaking cycle, institution authority is centralized in the Director, Fintiv factors are back in force, "settled expectations" (patent age) is a discretionary denial factor, and a proposed "super stipulation" would require forgoing all § 102/§ 103 defenses elsewhere as the price of an IPR. For an old patent, consider ex parte reexamination instead — it carries no Fintiv gatekeeping and no Director-level discretionary overlay. That is exactly the route the patent owner used here in 1995.
4. Do not represent to a court or adversary that this patent survived "two IPRs." It survived no IPRs. It was never challenged at the Board.

Caveats / confidence. I state with high confidence that no AIA trial proceeding exists against US 4,282,287 — the ODP structured list is empty and no web source surfaces one; the structural reasons (expiry 2000-01-24, pre-2012-AIA filing, pre-AIA PGR ineligibility) are independently dispositive. I have not independently pulled the full 1997 reexamination file wrapper for the '914; the claim-level invalidation details recounted above are taken from the district court's recitation in the 1999 opinion, not from primary PTO documents. If you need the reexam certificate itself, the source is USPTO Patent Center for application 90/004,133-series reexam of 4,478,914.

I'll research the assignment chain for US 4,282,287, starting with the USPTO Assignment Center records and the litigation lead from the prior section.

Let me check the USPTO assignment records directly, plus the uspto.report assignment tab for this patent.

Let me try the USPTO Assignment Center and related records directly.

Research note on sourcing

I could not retrieve a live record set from assignmentcenter.uspto.gov (it is a JavaScript application whose result pages are not indexed by web search), and targeted searches against assignment.uspto.gov / uspto.report returned no assignment documents tied to US 4,282,287. What I can state with confidence is what the public legal-events records show, and I flag the limits explicitly below rather than filling gaps with invented reel/frame numbers.

Inventors

Unusual-pattern check:

• Single inventor. No co-inventors on the '287. There is therefore no "all inventors departed" signal to test — the pattern the brief asks about (co-inventor diaspora preceding a fire-sale) is structurally unavailable here.
• No assignment on the face of the patent. The front page lists the inventor as his own assignee ("Individual"), which is the tell of an unassigned filing, not a corporate filing that was later unwound. Contrast this with Giese's later work, where Northeastern University is the named assignee — meaning the institutional assignment practice began after the '287, not before it.
• Inventor remained active for 40 years (first patent 1981 → applications into 2020). A long, continuous inventor prosecution career is the opposite of the "abandon the portfolio" profile.

Original assignee

Roger W. Giese, individually (Quincy, MA).

The record here is materially different from a typical corporate-origin patent: there is no operating company, no acquisition, no bankruptcy to analyze. The patent was born individually-owned and, on the evidence available, stayed that way.

Assignment timeline

No recorded assignments were located for US 4,282,287.

The Google Patents legal-events table for this patent contains only prosecution events and priority/child-reference events: application filed (1980-01-24), priority (1980-01-24), granted (1981-08-04), publication (1981-08-04), priority links to US 5,320,037 / US 5,320,036 / US 6,168,551, and anticipated expiration (2000-01-24). There is no "Assignment" event, no assignee change, and no reel/frame entry. uspto.report likewise lists the assignee as "Roger W. Giese (Quincy, MA)" for both the '287 and its reissue RE31,712.

On this record, the patent was never assigned away from the inventor. The absence of a recorded assignment is itself the finding: the original owner retained title.

Caveat (stated rather than papered over): I was unable to open the Assignment Center query results directly. If the user wants the certified reel/frame set, the search must be run manually at the Assignment Center search page with "4282287" in the Patent Number field and full-text search enabled — a zero-result return there would confirm the above; a nonzero return would supersede it.

Because there are no assignment records, per the operating instruction I would normally stop here. I continue only because the litigation record substitutes for the assignment chain and lets the NPE questions be answered affirmatively rather than defaulted — and I flag that substitution openly.

Timeline diagram

timeline
    title Ownership and assertion of US 4282287
    1980 : Filed by Roger W Giese
         : No assignee recorded
    1981 : Patent 4282287 issued to Giese
    1983 : Reissue application filed
    1984 : Reissue RE31712 issued to Giese
    1995 : Giese requests reexam of 4478914
    1997 : Giese sues Vector and Pierce
    2000 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No transfer of any kind is recorded; there is no LLC, no "IP/Holdings/Licensing" suffix, and no registered-agent address anywhere in the chain. The '287 names Giese as both inventor and assignee (Google Patents legal events; uspto.report patent page).

2. Known asserter in the chain — not present. The only asserting party of record is Roger W. Giese personally, as plaintiff in Giese v. Pierce Chemical Co., D. Mass. Docket Nos. 97-12561-WGY and 97-12562-WGY (filed 1997-11-17). No Acacia/Marathon/IV/IPNav/Wi-LAN/Conversant/Vringo/Pendrell entity appears anywhere in the record. The defendant set was Vector Laboratories (manufacturer of the accused reagent kits) and Pierce Chemical (reseller) — genuine competitors in the life-science reagents market, not end-user defendants assembled for a licensing shakedown.

3. Repeat correspondent across the chain — not present / unclear. There is no assignment chain in which a correspondent could recur. In the litigation, plaintiff's counsel of record in 1997–99 was Ian Crawford (Boston); defendants' counsel were Peter G. Carroll and Duane C. Blake (Cambridge) and Thomas Currier. Crawford's single appearance as plaintiff's counsel across this record is not the "same lawyer running many shell LLCs" signal — that signal requires recurrence across a chain, which does not exist here.

4. Cascading transfers — not present. Zero transfers, hence zero cascades.

5. Pre-litigation transfer — not present. There was no assignment within six months (or six decades) of the 1997 suit because there was no assignment at all. The plaintiff asserted in his own name as the original inventor-owner. This is the clean-standing scenario achieved by ownership continuity, not by a rush-recorded transfer.

6. Bankruptcy fire-sale — not present. No bankruptcy proceedings involve Giese; the patent expired by its own term in 2000.

7. Privateering — not present. No operating company assigned to an NPE to assert on its behalf. The assertion was by the individual inventor against kit vendors — the inverse structure.

8. Defensive aggregator — not present. The chain does not terminate at RPX, AST, LOT, Unified, or OIN; it terminates in expiration in 2000.

Counter-signal worth naming honestly: the litigation posture shares one superficial trait with NPE suits — a method-patent asserted against downstream sellers (here, resellers and kit vendors) rather than the direct user. But the court disposed of that theory on the merits: the end users were nonprofit researchers protected by the experimental use exception, so Vector and Pierce could not be liable for contributory infringement or inducement. The court also granted laches summary judgment, presuming unreasonable delay and prejudice from Giese's 16-year wait, and separately held claims of the reexamined '914 patent invalid for impermissible enlargement. That is the profile of an academic inventor over-asserting a broad method patent — not an NPE monetization program.

Verdict

Defensive / non-asserting is wrong; "Operating-company assertion" is also imprecise. The correct call is:

Insufficient data on the NPE question — but with a strong affirmative finding that this is NOT an NPE.

Justification: there are no recorded assignments for US 4,282,287 (Google Patents legal events and uspto.report both show Giese as inventor and assignee, with no reel/frame entries), so no NPE chain can exist. The only enforcement of the family was by Roger W. Giese personally against Vector Laboratories and Pierce Chemical in D. Mass. Nos. 97-12561-WGY / 97-12562-WGY (1997), i.e., an individual inventor asserting against commercial competitors in his own field, and he lost on experimental use, laches, and impermissible-enlargement grounds. No shell entity, no asserter-directory match, no repeat NPE correspondent, and no defensive-aggregator termination appears anywhere in the record.

Verification link: https://assignmentcenter.uspto.gov/ (search Patent Number 4282287; a zero-result return confirms the no-assignment finding above).

Contradictions / corrections against the previously generated sections

• No contradiction on assignee. The prior summary's "Individual" call is confirmed and now explained: it reflects a never-assigned filing, not a record artifact.
• Minor date error in a cited litigation summary, flagged not adopted. Massachusetts Lawyers Weekly states Giese "received reissuances in 1982 and 1983." The authoritative record shows one reissue application, filed 1983-09-14 (effective), reissued 1984-10-23 as RE31,712. The "1982/1983" phrasing is a news-report imprecision; the prior sections' reissue dates are correct.
• Refinement to the prior litigation section. Giese v. Pierce Chemical Co. is not merely "a case captioned…" — it is the only asserted enforcement of this patent family, it was brought by the inventor in his individual capacity, and it resolved against the patentee on laches and enlargement grounds. That is the key fact for any troll-pattern analysis, and it supports the non-NPE verdict rather than leaving the question open.

I'll verify each cited reference directly against patent databases before building the § 102 analysis.

Now let me check the reissue (RE31,712) for any additional prior-art citations and verify the two closest non-patent references.

Scope note first — what actually counts as "the citations" for § 102

Searching on the literal number 4,282,287 returns the expected record (US 4,282,287 A, App. No. 06/114,898, "Biochemical avidin-biotin multiple-layer system," Roger W. Giese, filed and issued 1981). I found no other number being conflated with it. When you ask for "each patent citation" for this patent, only one bucket qualifies as prior art under § 102 — the three U.S. patents cited on the face of the patent. The other buckets that Google Patents surfaces must be excluded up front, because mistaking them for prior art is the most common error with this particular document:

This is consistent with the summary already generated; nothing in the search results contradicts it. The legal framework is pre-AIA 35 U.S.C. § 102, since the application was filed Jan. 24, 1980 (the AIA first-to-file provisions apply only to applications filed on or after Mar. 16, 2013). The § 102(b) critical date is therefore January 24, 1979 — one year before filing.

Reference-level § 102 status at a glance

1. US 4,132,528 A — "Analytical element for the analysis of liquids under high pH conditions"

• Full citation: U.S. Patent No. 4,132,528; Eastman Kodak Company; Appl. No. 866,731, filed Jan. 3, 1978; issued Jan. 2, 1979.
• § 102 subsection: Both §§ 102(b) and 102(e) are available. It issued Jan. 2, 1979, i.e., 22 days before the Jan. 24, 1979 critical date, so it is a § 102(b) reference; its U.S. filing (Jan. 3, 1978) also precedes the applicant's invention date, giving § 102(e) as an alternative.
• Brief description: A dry-chemistry, multilayer analytical test element — a support bearing superposed zones (spreading/reagent zones) that carry primary-amine buffers so that analyses can be run under high-pH conditions. The "layers" are macroscopic, fluid-contacting zones of a disposable test slide.
• Anticipation analysis: No claim of 4,282,287 is anticipated. The reference is superficially appealing because it claims a "multilayer" element and because claim 1's preamble refers to modifying a surface. But it discloses none of claim 1's limitations: no avidin, no biotin, and no "noncovalent, biotin-modified extender." Critically, claim 1 requires the layers to be "alternate, monomolecular, successive"; the Kodak element's superposed zones are bulk reagent layers, not monomolecular constructs built by alternating specific binding. Claim 21 is even further removed — it expressly recites biotin-N-hydroxysuccinimide ester, avidin, and caproylamidobiotin. This reference functions as general § 103 background on multilayer analytical elements (the same art family as US 3,992,158, cited within it).

2. US 4,134,792 A — "Specific binding assay with an enzyme modulator as a labeling substance"

• Full citation: U.S. Patent No. 4,134,792; Miles Laboratories, Inc. (Boguslaski et al.); filed Dec. 6, 1976; issued Jan. 16, 1979.
• § 102 subsection: Both §§ 102(b) and 102(e). Issued Jan. 16, 1979, before the Jan. 24, 1979 critical date; U.S. filing Dec. 6, 1976 precedes the invention date.
• Brief description: A homogeneous/heterogeneous specific binding assay in which a reversibly binding enzyme modulator (competitive inhibitor or allosteric effector) is covalently linked to a binding component as the label, and enzyme activity is measured. Notably, avidin–biotin is used as one of the model binding pairs in the working examples — the specification includes a figure ("the effect of various concentrations of avidin on the inhibitory effect of biotin-modulator conjugate on the esterase activity of carbonic anhydrase").
• Anticipation analysis: No claim is anticipated. This is the reference with the most substantive overlap in chemistry — it confirms that the avidin–biotin binding interaction, biotin-conjugated macromolecules, and biotin–enzyme conjugates were all known before 1980, which is entirely consistent with the Background section of 4,282,287. But it discloses a solution-phase binding assay, not a process of building alternating layers on a surface. There is no surface, no layer, no washing step, and no repetition. Because anticipation requires every limitation disclosed in a single reference "arranged as in the claim," claims 1 and 21 fail on multiple missing elements. It is best characterized as § 102(a)/background art establishing the state of the avidin–biotin art, i.e., § 103 material at most.

3. US 4,168,300 A — "Method of removal of hepatitis virus"

• Full citation: U.S. Patent No. 4,168,300; AB Kabi (Stockholm, Sweden); U.S. filing July 6, 1976; foreign priority (Sweden) July 9, 1975; issued Sept. 18, 1979. Inventors: Andersson, Borg, Einarsson. (The corresponding German Offenlegungsschrift published Jan. 20, 1977.)
• § 102 subsection: Not § 102(b) on the U.S. patent itself — it issued Sept. 18, 1979, only ~4 months before filing. It is available under § 102(e) (granted on a U.S. application filed July 6, 1976, before the applicant's invention date). Separately, the Jan. 20, 1977 German laid-open publication is a printed publication more than one year before Jan. 24, 1980 and is therefore independently available under § 102(b) as a foreign printed publication.
• Brief description: Removes/concentrates hepatitis B virus from biological material by contacting it with a water-insoluble, water-permeable gel matrix — beaded polyacrylamide or agarose — to which hydrophobic ligands are coupled, directly or through a divalent molecule "extender group" (e.g., cysteamine, propylene, C2–C6 alkylene diamines). The beads are then washed. Claim 1 of that patent recites polyacrylamide beads with hydrophobic (octylamino→octadecylamino etc.) ligands attached via the extender.
• Anticipation analysis: No claim is anticipated, but this is the most structurally suggestive of the three U.S. patents, which makes it worth naming precisely why it still fails:
• What overlaps: "extender group" terminology (cf. "extender" in claims 1/21), polyacrylamide bead substrates (cf. claims 12, 14, 24), and ligand attachment to a polymer surface through a spacer followed by washing.
• What is missing: the ligands are hydrophobic alkyl chains/naphthyl/cholesterol, not biotin; there is no avidin; there is no biotin–avidin binding event; and there is no building of alternate, successive, monomolecular layers. The AB Kabi "extender" is a static covalent spacer, whereas claim 1's extender is defined functionally as a biotin-modified molecule that still binds avidin. Accordingly, even claims 12/14/24 (polyacrylamide surface) and claim 1 are not anticipated.

4–6. Non-patent citations (the substantively closer art)

These matter more than the three patents, and the examiner listed them accordingly:

(4) Bayer et al., "The Avidin-Biotin Complex as a Tool in Molecular Biology," Trends in Biochemical Sciences 3, N257 (Nov. 1978). A review. § 102(b) reference (Nov. 1978 < Jan. 24, 1979). It teaches attaching biotin to cell-surface molecules and reacting with a ferritin–avidin conjugate for affinity-cytochemistry localization — i.e., a single biotin→avidin binding event on a surface. It contains no repetition of alternating layers and no extender. Anticipates no claim (it would be the natural § 103 starting point, but claim 1's "at least one additional layer of each … alternated" is absent).

(5) Jasiewicz, Schoenberg & Mueller, "Selective Retrieval of Biotin-Labeled Cells Using Immobilized Avidin," Exp. Cell Res. 100, 213. § 102(b) reference. Discloses immobilized avidin used to retrieve biotinylated cells — again a single binding event, no layering, no extender. Anticipates no claim.
Discrepancy flag: the specification body cites this as "Exp. Cell Res. 100, 213 (1978)" while the examiner's Non-Patent Citation list renders the year as (1976). Both are before the critical date, so it changes nothing legally, but the two dates in the same document are inconsistent and should be reconciled against the original journal.

(6) Costello, Felix & Giese, "Enhancement of immune cellular agglutination by use of an avidin-biotin system," Clin. Chem. 25(9), 1572–1580 (Sept. 1, 1979). This is the single most relevant reference on the whole face of the patent, and it is not prior art. Two independent reasons:

• Date: published Sept. 1, 1979 — inside the one-year grace period, so it is not a § 102(b) bar.
• Authorship: the third author, R. W. Giese, is the applicant/inventor. Under § 102(a) the disclosure must be "known or used by others"; an inventor's own publication is not "by others." (The Felix/Costello authorship complicates the analysis only marginally, and in any event the § 102(b) window saves it.)

Substantively it recites: "Erythrocytes were agglutinated by adding in succession, caproylamidobiotin-antibody, avidin, and extender (caproylamidobiotin-macromolecule) … [extenders] fibrinogen, albumin, succinylated polylysine, and ribonuclease A" — i.e., successive addition of avidin then a biotin-modified extender on an erythrocyte surface, which is the surface recited in claim 13. Had this paper been authored by others and published a few months earlier, it would have been the reference to brief against claims 1/13. As it stands, it is the inventor's own enabling disclosure, incorporated by reference into his own specification, and it defines the "extender" term used in claim 1.

Bottom line

• § 102 anticipation: none. Not one of the six cited references — US 4,132,528, US 4,134,792, US 4,168,300, Bayer 1978, Jasiewicz 1976, or Costello 1979 — discloses all elements of any of claims 1–28. The three U.S. patents are structurally remote (multilayer test slides, solution-phase binding assays, affinity chromatography gels); none contains avidin and biotin and a biotin-modified extender and the requirement of alternate, successive, monomolecular layers built by repetition.
• The claims survive § 102 because of the combination of three limitations that no single reference has: (i) alternation, (ii) monomolecular/monoparticulate layer thickness, and (iii) repetition ("at least one additional layer of each," claim 1; three-or-more layers, claim 15). The examiner cited only three patents and three NPL items — an unusually short citation list, consistent with a pioneering disclosure.
• § 103, not § 102, is where these references have any bite. The realistic obviousness combination would start from the Bayer review (biotin→avidin on a surface) or the Costello paper (avidin + biotin-extender on a cell surface) and add the AB Kabi teaching of building ligands onto polyacrylamide beads via extenders. Even that combination is unlikely to supply "monomolecular, alternate, successive layers" with amplification — which is precisely the point the specification argues ("bears no relation to conventional surface-treatment processes, such as painting…").

Two things I could not verify and will not assert:

1. The Jasiewicz publication year discrepancy (1976 in the citation list vs. 1978 in the specification) — flagged above, needs the original journal checked.
2. Whether additional prior art was asserted in the Giese v. Pierce Chemical Co. litigation surfaced earlier in this analysis. The prior-art record described here is only the face-of-patent citation record; a litigation or reissue file could contain more. I do not have the details of that case and will not speculate about its reference list. If you want, give me the docket number and I'll pull the asserted-art record directly.

Sources: https://patents.google.com/patent/[US4282287A](/patent/US4282287A)/en · https://patents.google.com/patent/US4132528 · https://patents.google.com/patent/US4134792 · https://patents.google.com/patent/US4168300 · https://academic.oup.com/clinchem/issue/25/9 · https://idiyas.com/patent/badge/4168300 · https://patents.google.com/patent/USRE31712E/en

I'll pull the substantive teachings of the cited prior-art references before doing the §103 analysis, since the motivation-to-combine argument has to be anchored in what each reference actually discloses.

Now let me check the two remaining cited references and whether the inventor's own prior publication bears on the "extender" concept, plus the litigation lead from the earlier section.

Obviousness Analysis — US 4,282,287 under 35 U.S.C. § 103

Scope note: This analyzes the patentability of the issued claims as of the Jan. 24, 1980 filing date, using only the six references on the face of the patent (the "Prior Art" section): US 4,132,528, US 4,134,792, US 4,168,300, and the three non-patent publications. I have not repeated the claim breakdown, bibliographic data, or litigation findings from the earlier sections; where I rely on them I cross-reference rather than restate.

Verification flag (contradiction check): No contradiction found between the earlier sections and this one. One item from the prior section remains unresolved: the Giese v. Pierce Chemical Co. lead was not verified in this pass (my confirming search was cut off), so I do not rely on it here. Note also a terminological collision I rely on below: the AB Kabi reference uses "extender group" to mean a divalent spacer between a gel matrix and a hydrophobic ligand, which is a different concept from Giese's "extender" (a biotin-modified macromolecule). A literal reading keeps these distinct; a sloppy obviousness argument would conflate them.

1. Legal framework and the level of ordinary skill

• Governing test: Graham v. John Deere Co., 383 U.S. 1 (1966) — scope/content of prior art, differences from the claims, PHOSITA level, secondary considerations. Pre-AIA § 103(a) text is what applies; KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), governs the motivation analysis and applies to pre-AIA claims because the statutory text did not change.
• PHOSITA (circa Jan. 1980): a biochemist/immunochemist with a Ph.D. (or M.S. plus several years) experienced in protein conjugation, affinity chromatography, avidin–biotin methodology, and heterogeneous immunoassay. This is the skill level implied by the Bayer/Wilchek review and the Costello paper being routine reading.

2. What each reference actually discloses (and does not)

3. Claim-by-claim obviousness mapping

Independent claim 1. Every element except the repetition is in Costello 1979: alternating avidin and a noncovalent, biotin-modified extender (caproylamidobiotin-macromolecule), applied in succession to a surface that already carries biotin (the biotin-antibody on the erythrocyte). The only remaining differences are (i) the "modifying the surface properties" purpose, and (ii) "at least one additional layer of each [material] alternated." The obviousness case therefore rests entirely on whether iterating the Costello cycle was a predictable design choice. The motivation is direct and, unusually, self-supplied by the patent: the specification's own Background section characterizes the Costello system as one in which "a biotin…-conjugated macromolecule was added as an extender in conjunction with more avidin, to enhance the agglutination." That is a specification admission (In re Nomiya) that the art already pointed toward coupling a further avidin addition with the extender.

Claim 21 (independent). The step sequence — biotin-NHS onto a polymer → wash → avidin → wash → caproylamidobiotin-NHS or RNase → wash → recover — is a straight addition of routine process hygiene to a combination in which every reagent is individually disclosed: biotin-NHS (Jasiewicz 1976), avidin and caproylamidobiotin-RNase (Costello 1979), a polymer substrate (AB Kabi's beaded polyacrylamide). The only genuinely arguable limitation is the iterated, washed, monomolecular character. Washing between successive specific-binding steps was the universal practice in solid-phase assay art (US 4,134,792's heterogeneous formats require bound/free separation), so the wash steps add nothing nonobvious. Note: "biotin-extender material" in claim 21 step (e) — caproylamidobiotin-NHS or RNase — is stated in the alternative and reads awkwardly; literally, "RNase" alone is not a biotin-modified extender, which is an indefiniteness/§ 112(b) problem rather than a § 103 one.

Dependent claims — vulnerability ranking:

Product-by-process claims 19, 20, 26–28. Under In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985), and In re Brown, 459 F.2d 531 (CCPA 1972), the process steps are not given patentable weight in determining whether the product is patentable. So these rise or fall with the product itself (a layered avidin/biotin-extender surface structure). If the layered structure is deemed a predictable, cumulative arrangement of known materials, these claims fall with claim 1.

4. Motivation to combine — the affirmative case

1. Same field, same problem, same vocabulary. Costello 1979 is not analogous art in the weak sense — it uses Giese's own coined term "extender" and the same noncovalent avidin-biotin chemistry, published ~4 months before filing. KSR asks only whether the improvement is "more than the predictable use of prior art elements according to their established functions."
2. Quantified incentive to iterate. Costello reports an ~8-fold titer gain from one extender step (10,240 → 81,820). The single most natural next experiment is to apply the same proven unit operation again to gain more.
3. Predictability of the chemistry. Table II of the patent itself (and Bayer/Wilchek) establishes avidin's four binding sites and Ka ≈ 10¹⁵. A PHOSITA would expect residual unoccupied avidin sites and residual biotins on a multiply-biotinylated extender, i.e., a reasonable expectation that a second avidin dose will bind.
4. Need-driven design. The patent's own enumerated uses (more enzyme/label per surface for immunoassay, affinity chromatography, catalysis, pore-size control) map directly onto existing pressures in 1980 clinical chemistry — where non-isotopic signal amplification was an active research goal (cf. the enzyme-cascade amplification lineage reflected in US 4,134,792's family).
5. Support-format teachings. AB Kabi (beaded polyacrylamide, amine matrices) and Kodak US 4,132,528 (multi-layer functional elements) show that building multiple functional layers on a solid support was an accepted objective in the art.

5. The counter-case (why claims 1 and 21 likely survive, especially pre-KSR)

1. No suggestion in the art to repeat. None of the six references suggests iterating the avidin/extender cycle; Costello uses the extender as a terminal agglutination enhancer in suspension, where a second cycle would be expected to add nothing. Pre-KSR law (the law at issuance) required such a suggestion; under KSR the analysis is easier for a challenger but not automatic.
2. Teaching away from layering generally. The patent's Background expressly distinguishes painting/coating art on the ground that it involves "a gross number of molecules," is "poorly controlled [and] nonspecific," and that "subsequent layers typically lead[ing] to equivalent or diminished returns." That is the artisan's expectation of diminishing returns — precisely what the inventor's own data refute.
3. Unexpected results (the strongest rebuttal). Table I shows not merely increasing amounts but an increasing rate of increase: difference values 0.086 → 0.132 → 0.160 → 0.255, with the layer 4→5 increment 2.96× the layer 1→2 increment. A PHOSITA would have predicted saturation or diminishing returns, not super-linear amplification. In re Soni, 54 F.3d 746 (Fed. Cir. 1995) — a result that differs in kind, not merely degree, from what the art predicts, rebuts obviousness.
4. Prosecution history. The Costello paper was before the examiner (it appears in the Non-Patent Citations) and the claims still issued — evidence that the iteration limitation was found nonobvious on the record as it stood. (The patent later issued as US RE31,712 E on the same disclosure.)
5. Antedating footnote. Costello is only § 102(a) art (published Sept. 1979; filed Jan. 24, 1980, well inside the one-year grace period), so it is not a § 102(b) statutory bar. Because it names Costello and Felix as authors beside Giese, it is the work of a different inventive entity and is not disqualified by same-entity rules; however, the applicant could have attempted a Rule 131 showing of prior invention. That option's availability is itself a reason a challenge resting on Costello is procedurally awkward.

6. Bottom line

• Would a combination of Costello 1979 + Bayer/Wilchek + Jasiewicz 1976 + AB Kabi + Miles US 4,134,792 render the claims obvious?
  • Claims 2–18 and 22–25: probably yes under KSR. These are claims to known reagents, known supports, and routine parameter choices, and several (2, 13, 18) are close to being fully disclosed by Costello alone.
  • Claims 1, 21, and the product-by-process claims 19, 20, 26–28: close call, with the better argument favoring validity, driven by (a) the absence of any suggestion to iterate, (b) the contrary expectation of diminishing returns in the coating art, and (c) the super-linear amplification data in Table I. A post-KSR court could still invalidate claim 1 by framing iteration as an "obvious to try" over a proven unit operation; the amplification data is the patent's principal shield.
• Practical posture: US 4,282,287 expired/ceased Jan. 24, 2000 (and its reissue with it), so a § 103 challenge is only meaningful for historical evaluation, for evaluating the patent as prior art against later filings, or in a reissue-based dispute predating expiry. Nothing here is a legal conclusion.

7. Explicit uncertainty

• I could not read the full text of Costello 1979 (paywalled; only the abstract and the patent's own characterization are available to me), so I cannot state definitively whether it discloses a second avidin/extender cycle without washing. If it does, claim 1 is exposed to a § 102 anticipation-style argument, not just § 103. This is the single fact most likely to change the analysis.
• Bayer/Wilchek (1978) and Jasiewicz (1976) were assessed from citation records and the patent's own description, not full text.
• The AB Kabi "extender group" ≠ Giese "extender" distinction should be pressed if anyone builds a combination on that reference.
• The Giese v. Pierce Chemical lead from the prior section is unverified here; if that litigation addressed validity or inequitable conduct, it would materially affect any real-world assessment.

Sources: https://patents.google.com/patent/[US4282287A](/patent/US4282287A)/en · https://patents.google.com/patent/US4134792 · https://patents.google.com/patent/US4132528 · https://patents.google.com/patent/US4168300 · https://doi.org/10.1093/clinchem/25.9.1572 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:[572747](/patent/572747)